Advanced Enzyme Tech
312.90
+14.10(+4.72%)
Market Cap₹3,502.19 Cr
PE Ratio21.48
IndustryHealthcare
Company Performance:
1D+4.72%
1M+3.37%
6M+2.71%
1Y-3.14%
5Y-15.24%
View Company Insightsright
More news about Advanced Enzyme Tech
12Nov 25
Advanced Enzyme Technologies Unveils Global Growth Strategy Focusing on Human Nutrition and Expansion
Advanced Enzyme Technologies has announced a comprehensive strategy for global growth, focusing on human nutrition, animal health, and bio-processing. The plan includes new product launches, increased R&D spending, and expansion of distribution networks in the US and Europe. The company reported strong financial performance with 26% year-on-year revenue growth to ₹1,845.00 million in Q2 FY26. Human Nutrition, the largest segment, contributed 66% to total revenue. The company is expanding capacity in India and Mexico and sees significant growth in international markets, particularly in Europe and Asia.
 no imag found
12Nov 25
Advanced Enzyme Technologies Reports Impressive Q2 Performance with 41% EBITDA Surge
Advanced Enzyme Technologies, a leading enzyme manufacturer, reported robust Q2 financial results. Revenue increased by 23% to 1,850.00 crore, EBITDA grew 41% to 600.00 crore, and consolidated net profit rose 32% to 434.00 crore year-over-year. The company's EBITDA margin expanded by 3.55 percentage points to 32.55%, indicating improved operational efficiency and cost management.
 no imag found
22Sept 25
Advanced Enzyme Technologies Presents at DAM Capital Pharma Conference
Advanced Enzyme Tech, a global leader in enzyme and probiotic manufacturing, will participate in the DAM Capital Advisors Limited Pharma and Healthcare conference on September 23, 2025. The company has submitted its presentation materials to stock exchanges. Advanced Enzyme Tech operates 9 manufacturing units, 7 R&D facilities across India, USA, and Germany, and serves over 700 clients in 68 countries. The company reported revenue of ₹6,369.00 million with an EBITDA margin of 31.00% in its latest financial results.
 no imag found
02Aug 25
Advanced Enzyme Technologies Reports 20% Revenue Growth in Q1 FY26
Advanced Enzyme Tech (AETL) reported strong Q1 FY26 results with consolidated revenue up 20% to ₹1,859.00 million. Net profit increased 16% to ₹404.00 million. Human nutrition segment grew 21%, contributing 66% to total revenue. Animal nutrition saw 51% growth. Domestic sales increased 32%, while international sales grew 9%. EBITDA margin stood at 30.00% and PAT margin at 22.00%.
 no imag found
25Jul 25
JC Biotech, Subsidiary of Advanced Enzyme Tech, Approves Solar Power Investment Partnership with Raywatt Solar
JC Biotech, a 95.72% subsidiary of Advanced Enzyme Tech, has approved a collaboration with Raywatt Solar Power Systems to develop a group captive solar power project. JC Biotech will invest up to ₹10 million for a 26% stake in a Special Purpose Vehicle company set up for this project. The solar power will supply electricity to JC Biotech's plant in Andhra Pradesh. The project is expected to be completed by March 31, 2026, aiming to provide a sustainable and cost-effective power source while reducing the company's carbon footprint.
 no imag found
04Jul 25
Advanced Enzyme Technologies Expands into Nutrition and Wellness with New Subsidiary
Advanced Enzyme Technologies has established a new subsidiary, Advanced Nutrazyme Pvt Ltd, to strengthen its presence in the nutrition and wellness sector. This strategic move aims to capitalize on the growing demand for nutritional and wellness products, leveraging the company's expertise in enzyme technology. The new subsidiary is expected to develop specialized products for health-conscious consumers, potentially opening up new revenue streams and market opportunities for the parent company.
 no imag found
13May 25
Advanced Enzyme Tech Reports Mixed Q4 Results with Revenue Growth and Profit Dip
Advanced Enzyme Tech's Q4 results show revenue growth of 8.28% YoY to ₹1.70 billion, but profitability declined. EBITDA decreased by 17.36% to ₹457.00 million, with EBITDA margin contracting to 27.33% from 35.06%. Net profit slightly decreased by 6.36% to ₹265.00 million. The company faces challenges in maintaining profit margins despite top-line growth.
 no imag found
13Mar 25
Advanced Enzyme Technologies Gears Up for Analyst and Investor Meeting
Advanced Enzyme Technologies Ltd (AETL) has announced a virtual one-on-one meeting with Raintree Family Office on March 19, 2025. The meeting, disclosed in compliance with SEBI regulations, aims to provide updates on company performance and discuss future strategies. While the specific agenda is not revealed, such meetings typically cover recent financial results, market trends, and company outlook. The announcement has sparked interest among investors and market watchers, potentially impacting short-term stock performance. AETL's Company Secretary emphasized their commitment to stakeholder transparency by uploading the meeting information on the company website.
 no imag found
Advanced Enzyme Tech
312.90
+14.10
(+4.72%)
1 Year Returns:-3.14%
Industry Peers
Anthem Biosciences
693.25
(+2.45%)
Advanced Enzyme Tech
312.90
(+4.72%)
Genesis IBRC
72.94
(-4.99%)
Vivo Bio Tech
28.94
(-0.21%)